Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 14/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 10/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ATP4A | P20648 | 2/20 | 0.43 |
| ▸ | ATP4B | P51164 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5402140 | 0.91 | HRH4 (0.46) | MAPK1MAPK10ADORA1ADORA2AGFER | |
| SCHEMBL5401255 | 0.91 | MAPK1 (0.51) | MAPK1ADORA1ADORA2AGFERKMT2A | |
| SCHEMBL5396033 | 0.91 | ADORA1 (0.46) | MAPK1MAPK10ADORA1ADORA2AGFER | |
| SCHEMBL5392519 | 0.90 | TACR3 (0.48) | ADORA1ADORA2AGFERKMT2A | |
| SCHEMBL5407464 | 0.90 | L3MBTL3 (0.47) | MAPK1MAPK10ADORA1ADORA2A | |
| SCHEMBL4761520 | 0.89 | MAPK1 (0.64) | MAPK1MAPK10ADORA1ADORA2AATP4A | |
| SCHEMBL5395571 | 0.89 | ALOX5AP (0.43) | MAPK1MAPK10ADORA1ADORA2AGFER | |
| SCHEMBL7089512 | 0.88 | MAPK1 (0.60) | MAPK1MAPK10ADORA1ADORA2A | |
| SCHEMBL5415801 | 0.86 | ALDH1A1 (0.53) | MAPK1KMT2ATSHR | |
| SCHEMBL5398877 | 0.86 | MAPK1 (0.54) | MAPK1ADORA1ADORA2AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363906-B1 | HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMA (US) | 2015-07-15 | — | — | EP | claimed |
| US-6743791-B2 | ANTICANCER AGENTS; ANTIINFLAMMATORY AGENTS | VERTEX PHARMACEUTICALS INCORPORATED | 2004-06-01 | — | — | US | claimed |
| US-20030092714-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-15 | — | — | US | claimed |
| EP-1363906-B1 | HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMA (US) | 2015-07-15 | — | — | EP | disclosed |
| US-7253187-B2 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-07 | — | — | US | disclosed |
| US-20040229875-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-11-18 | — | — | US | disclosed |
| CN-1494541-A | heterocyclic inhibitors of ERK2 and uses thereof | ��̩��˹ҩ��ɷ�����˾ | 2004-05-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229875-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | MAPK1, MAPK3, MAP2K2 | MAPK1 1/4885MAPK10 53/4885ADORA1 4106/4885 |
| US-20030092714-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | MAPK1, MAPK3, MAP2K2 | MAPK1 1/4885MAPK10 53/4885ADORA1 4106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.